Short-term Efficacy and Safety of Anlotinib for Advanced Non-Small Cell Lung Cancer★
Aimi HUANG,Weimin WANG,Jie QIAN,Zhiqiang GAO,Jianlin XU,Aiqin GU,Ruoyan QIN,Yuqing CAI
DOI: https://doi.org/10.3969/j.issn.2095-1264.2019.05.19
2019-01-01
Abstract:Objective To investigate the short-term efficacy and safety of anlotinib in the treatment of advanced non-small cell lung cancer (NSCLC) after multi-line failure. Methods Between February 2018 and November 2018, 53 patients with advanced NSCLC who got second line or above treatment were selected in this study. They had anlotinib hydrochloride capsules 12 mg daily at breakfast, orally, for 2 weeks, then withdrawal 1 week, 21 days as a treatment cycle, until disease progression or intolerance. Evaluate the curative effect after the second treatment cycle. During the treatment, the patients were observed for bone marrow suppression, hand-foot syndrome, hypertension, proteinuria, gastroin-testinal reaction, fatigue, liver dysfunction and other adverse reactions. Changes of the patients’ KPS and serum CEA levels before and after treatment were also analyzed. Results After oral administration of anlotinib hydrochloride for 2 cycles, no one achieved complete remission (CR). There were 24 cases of partial remission (PR), 19 cases stable (SD), and 10 cases in progression (PD). The efficiency (RR) was 45.28% (24/53) and the disease control rate (DCR) was 81.13% (43/53). Grade Ⅰ-Ⅱ adverse reactions during treatment included neutropenia, thrombocytope-nia, hand-foot syndrome, hypertension, proteinuria, gastrointestinal reactions, fatigue, and liver dysfunction, and the incidence was respectively 8.51% (5/53), 7.55% (4/53), 41.51% (22/53), 24.53% (13/53), 13.21% (7/53), 18.87% (10/53), 20.75% (11/53), 5.67% (3 /53). Grade Ⅲ ad-verse reactions included 1 case of hypertension, 2 cases of hand-foot syndrome. No grade Ⅳ adverse reactions, yet no drug-induced death. The KPS score was (72.39±12.50) before treatment, and was (76.62±13.83) after treatment. The KPS score after treatment was slightly higher than before treatment but the difference was not statistically significant (P>0.05). After treatment, the serum CEA was (12.09±3.31) ng·mL-1, and was statistically lower than before treatment which was (18.25±3.9) ng·mL-1(P<0.05). The treatment efficacy showed no significant correlation with gender, history of smoking, age, pathological type (P>0.05), but was correlated with driving gene status, clinical stage, and timing of select-ing anlotinib (P<0.05). Conclusion Anlotinib could improve the prognosis of advanced NSCLC after multi-line therapy, reduce serum CEA level, and prolong survival. The adverse reactions were controllable. Thus it is worthy of clinical promotion.